Angiotensin-(1-7) inhibitory mechanism of norepinephrine release in hypertensive rats

Hypertension

Volumn 44, Issue 5, 2004, Pages 783-787

  Gironacci, Mariela M ^a   Valera, María S ^a   Yujnovsky, Irene ^a   Peña, Clara ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Angiotensin; Angiotensin antagonist; Bradykinin; Kinins; Nitric oxide; Norepinephrine; Receptors, angiotensin II

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; ARGININE; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; GUANYLATE CYCLASE INHIBITOR; ICATIBANT; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; POTASSIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ESSENTIAL HYPERTENSION; HYPOTHALAMUS; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN I; ANIMALS; ANTIHYPERTENSIVE AGENTS; CYCLIC GMP-DEPENDENT PROTEIN KINASES; HYPERTENSION; HYPOTHALAMUS; NITRIC OXIDE; NOREPINEPHRINE; PEPTIDE FRAGMENTS; RATS; RATS, INBRED SHR; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTOR, BRADYKININ B2; SYMPATHETIC NERVOUS SYSTEM;

EID: 7244240604     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000143850.73831.9d     Document Type: Article

References (32)

1. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension. 1997; 30(part 2):535-541.
2. Santos RAS. Campagnole-Samos MJ, Andrade S. Angiotensin-(1-7): an update. Regul Pept. 2000;91:45-62.
3. 3H]- norepinephrine from rat atria. Hypertension. 1994;24:457-460.
4. Ferrario CM. Angiotensin-(1-7) and antihypertensive mechanisms. J Nephrot. 1998;11:278-283.
5. Poyner DR, Hawkins PT, Benton HP, Hanley MR. Changes in inositol lipids and phosphates after stimulation of the MAS-transfected NG115-401L-C3 cell line by mitogenic and non-mitogenic stimuli. Biochem J. 1990;271:605-611.
6. Santos RAS, Simoes e Silva AC, Maric C, Silva DMR, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes E, Lemos VS. Campagnole-Santos MJ, Schultheiss H, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G-protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100:8258-8263.
7. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999; 34(part 2):724-72S.
8. De Wardener HE. The hypothalamus and hypertension. Physiol Rev. 2001;81:1599-1658.
9. Singewald N, Philippu A. Involvement of biogenic amines and amino acids in the central regulation of cardiovascular homeostasis. Trends Pharmacol Sci. 1996;17:356-363.
10. Gironacci MM, Vatta M, Rodriguez-Fermepín M, Fernández B, Peña C. Angiotensin-(1-7) reduces norepinephrine release through a nitric oxide mechanism in rat hypothalamus. Hypertension. 2000;35:1248-1252.
11. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res. 1998;39:89-105.
12. Qualy JM, Westfall TC. Release of norepinephrine from the paraventricular hypothalamic nucleus of hypertensive rats. Am J Physiol. 1988;254: H993-H1003.
13. Santos RAS, Campagnole-Santos MJ, Baracho NCV, Fontes MAP, Silva LCS, Neves LAA, Oliveira DR, Caligiorne SM, Rodrigues ARV, Gropen C, Carvalho WS, Simoes e Silva AC, Khosla MC. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull. 1994;35:293-298.
14. Brosnihan KB. Effect of angiotensin-(1-7) peptide on nitric oxide release. Am J Cardiol. 1998;82:17S-19S.
15. Takeda K, Buñag RD. Sympathetic hyperactivity during hypothalamic stimulation in spontaneously hypertensive rats. J Clin Invest. 1978;62: 642-648.
16. Patel KP, Kline RL, Mercer PF. Noradrenergic mechanisms in the brain and peripheral organs of normotensive and spontaneously hypertensive rats at various ages. Hypertension. 1981;3:682.
17. Pacák K, Yadid G, Jakab G, Lenders JWM, Kopin IJ, Goldstein DS. In vivo hypothalamic release and synthesis of catecholamines in spontaneously hypertensive rats. Hypertension. 1993;22:467-478.
18. Reja V, Goodchild AK, Phillips JK, Pilowsky PM. Tyrosine hydroxylase gene expression in ventrolateral medulla oblongata of WKY and SHR: a quantitative real-time polymerase chain reaction study. Auton Neurosci. 2002;98:79-84.
19. Gironacci MM, Yujnovsky I, Gorzalczany S, Taira C, Peña C. Angiotensin-(1-7) inhibits the angiotensin II-enhanced norepinephrine release in coarcted hypertensive rats. Regul Pept. 2004;118:45-49.
20. Martin KA, Grant SGN, Hockfield S. The mas proto-oncogene is developmentally regulated in the rat central nervous system. Dev Brain Res. 1992;68:75-82.
21. Bunnemann B, Fuxe K, Metzger R, Mullins J, Jackson TR, Hanley MR, Ganten D. Autoradiographic localization of mas proto-oncogene mRNA in adult rat brain using in situ hybridization. Neurosci Lett. 1990;114: 147-153.
22. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999;33: 613-621.
23. Unger T. The angiotensin type 2 receptor: variations on an enigmatic theme. J Hypertens. 1999;17:1775-1786.
24. Takekoshi K, Ishii K, Shibuya S, Kawakami Y, Isobe K, Nakai T. Angiotensin II type 2 receptor counter-regulates type 1 receptor in catecholamine synthesis in cultured porcine adrenal medullary chromaffin cells. Hypertension. 2002;39:142-148.
25. Lucas KAL, Pitari GM, Kazrounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52:375-413.
26. Yun H, Dawson VL, Dawson TM. Neurobiology of nitric oxide. Crit Rev Neurobiol 1996;10:291-316.
27. Kojda G, Kottenberg K. Regulation of basal function by NO. Cardiovasc Res. 1999;41:514-523.
28. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 1998; 31(part2):349-355.
29. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925-935.
30. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995;26:164-170.
31. AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature. 2000;407:94-98.
32. Milligan G. G-Protein coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol. 2004;66:1-7.